# REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases

> **NCT07160231** · PHASE4 · RECRUITING · sponsor: **Sint Maartenskliniek** · enrollment: 200 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis (PsA)
- Axial Spondyloarthritis (AxSpA)

## Interventions

- **DRUG:** JAKi dose reduction strategy
- **DRUG:** JAKi disease activity guided continuation of same dose strategy

## Key facts

- **NCT ID:** NCT07160231
- **Lead sponsor:** Sint Maartenskliniek
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2028-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07160231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07160231, "REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07160231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*